{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:32:53Z","timestamp":1791484373942,"version":"4.3.4"},"reference-count":67,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T00:00:00Z","timestamp":1705795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Clinical trials of new drugs for tic disorders (TD) often fail to yield positive results. Placebo and nocebo responses play a vital role in interpreting the outcomes of randomized controlled trials (RCTs), yet these responses in RCTs of TD remain unexplored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim was to assess the magnitude of placebo and nocebo responses in RCTs of pharmacological interventions for TD and identify influencing factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic search of the Embase, Medline, Cochrane Central Register of Controlled Trials, and PsycINFO databases was conducted. Eligible studies were RCTs that compared active pharmacological agents with placebos. Placebo response was defined as the change from baseline in TD symptom severity in the placebo group, and nocebo response as the proportion experiencing adverse events (AEs) in this group. Subgroup analysis and meta\u2010regression were performed to explore modifying factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010four trials involving 2222 participants were included in this study. A substantial placebo response in TD symptom severity was identified, with a pooled effect size of \u22120.79 (95% confidence interval [CI] \u22120.99 to \u22120.59; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200967%). Forty\u2010four percent (95% CI 27% to 63%; <jats:italic>I<\/jats:italic><jats:sup><jats:italic>2<\/jats:italic><\/jats:sup>\u2009=\u200992%) of patients experienced AEs while taking inert pills. Sample size, study design, and randomization ratio were correlated with changes in placebo and nocebo responses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>There were considerable placebo and nocebo responses in TD clinical trials. These results are of great relevance for the design of future trials and for clinical practice in TD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p>PROSPERO registration ID CRD42023388397. \u00a9 2024 The Authors. <jats:italic>Movement Disorders<\/jats:italic> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/mds.29714","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T02:19:00Z","timestamp":1705889940000},"page":"585-595","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Placebo and Nocebo Responses in Pharmacological Trials of Tic Disorders: A Meta\u2010Analysis"],"prefix":"10.1002","volume":"39","author":[{"given":"Simeng","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pediatrics Guang'anmen Hospital, China Academy of Chinese Medical Sciences  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Xiong","sequence":"additional","affiliation":[{"name":"School of Acupuncture\u2010Moxibustion and Tuina Beijing University of Chinese Medicine  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehua","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Guang'anmen Hospital, China Academy of Chinese Medical Sciences  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Guang'anmen Hospital, China Academy of Chinese Medical Sciences  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Guang'anmen Hospital, China Academy of Chinese Medical Sciences  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Guang'anmen Hospital, China Academy of Chinese Medical Sciences  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Guang'anmen Hospital, China Academy of Chinese Medical Sciences  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine Children's Hospital of Soochow University  Soochow China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Chinese EQUATOR Center, Hong Kong Chinese Medicine Clinical Study Center, Chinese Clinical Trial Registry (Hong Kong) School of Chinese Medicine, Hong Kong Baptist University  Kowloon, Hong Kong SAR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8072-9701","authenticated-orcid":false,"given":"Fei","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Guang'anmen Hospital, China Academy of Chinese Medical Sciences  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,21]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2019.109675"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26089"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2012.11.013"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29454"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1194"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-021-01832-4"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40474-015-0063-5"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-021-01881-9"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.4317"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007467"},{"key":"e_1_2_8_12_1","unstructured":"Teva Announces Registration Trials of Deutetrabenazine in Pediatric Patients with Tourette Syndrome Did Not Meet the Primary Endpoint;2020. Available from:https:\/\/www.businesswire.com\/news\/home\/20200219005903\/en\/Teva-Announces-Registration-Trials-of-Deutetrabenazine-in-Pediatric-Patients-with-Tourette-Syndrome-Did-Not-Meet-the-Primary-Endpoint."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28681"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyab054"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X16666181026163922"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004004"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/10870547221075845"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2008.06.030"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.5.622"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.113"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01134-w"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13229-020-00372-z"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/07067437221115029"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_8_25_1","unstructured":"Otsuka Pharmaceutical Development & Commercialization Inc.A Multicenter Randomized Double\u2010blind Placebo\u2010controlled Study Evaluating the Safety and Efficacy of Fixed\u2010Dose Once\u2010weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder. clinicaltrials.gov;2021. Report No: NCT01418352. Available from:https:\/\/clinicaltrials.gov\/study\/NCT01418352."},{"key":"e_1_2_8_26_1","unstructured":"Otsuka Pharmaceutical Development & Commercialization Inc.A Multicenter Randomized Double\u2010blind Placebo\u2010controlled Study Evaluating the Safety and Efficacy of Flexible\u2010Dose Once\u2010weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder. clinicaltrials.gov;2021. Report No: NCT01418339. Available from:https:\/\/clinicaltrials.gov\/study\/NCT01418339."},{"key":"e_1_2_8_27_1","unstructured":"Neurocrine Biosciences.A Phase 2b Randomized Double\u2010Blind Placebo\u2010Controlled Dose Optimization Study to Assess the Safety Tolerability and Efficacy of NBI\u201098854 for the Treatment of Pediatric Subjects With Tourette Syndrome. clinicaltrials.gov;2021. Report No: NCT03325010. Available from:https:\/\/clinicaltrials.gov\/study\/NCT03325010."},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28204"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.29397"},{"key":"e_1_2_8_30_1","unstructured":"Neurocrine Biosciences.A Randomized Double\u2010Blind Placebo\u2010Controlled Study to Assess the Safety and Efficacy of NBI\u201098854 in Adult Subjects With Tourette Syndrome. clinicaltrials.gov;2020. Report No: NCT02581865. Available from:https:\/\/clinicaltrials.gov\/study\/NCT02581865."},{"key":"e_1_2_8_31_1","unstructured":"Neurocrine Biosciences.A Randomized Double\u2010Blind Placebo\u2010Controlled Study to Assess the Safety and Efficacy of NBI\u201098854 in Pediatric Subjects With Tourette Syndrome. clinicaltrials.gov;2020. Report No: NCT02679079. Available from:https:\/\/clinicaltrials.gov\/study\/NCT02679079."},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2016.0026"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2017.0024"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpp.12432"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12m08189"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/147323001003800119"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.185348"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000163279.39598.44"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000055434.39968.67"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000044058.64647.7E"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.7.649"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200202000-00006"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200211000-00009"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200109000-00020"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.7.1067"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200003000-00010"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1991.01810280040006"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25365"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1668"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2013.08.012"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00023-6"},{"issue":"2","key":"e_1_2_8_52_1","article-title":"Listening to Prozac but hearing placebo: a meta\u2010analysis of antidepressant medication","volume":"1","author":"Kirsch I","year":"1998","journal-title":"Prev Treat"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3923"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.04.015"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aap8488"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/PSY.0b013e3182294a50"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1907805"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08020247"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.12030315"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/s44220-023-00118-9"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2017.02.022"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000333"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05454-8"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc11919"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1159\/000365248"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2012.12.005"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.88"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2013.66"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.29714","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:43:13Z","timestamp":1760967793000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.29714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,21]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1002\/mds.29714"],"URL":"https:\/\/doi.org\/10.1002\/mds.29714","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,21]]},"assertion":[{"value":"2023-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}